Pakistan is the first interim applicant in the transition phase of the new funding model (NFM) to be awarded money. On 3 May, the Global Fund Board approved funding in the amount of $8 million. This is the same amount that was identified for Pakistan when the interim applicants were announced (see GFO article).
Procurement costs for HIV, TB and malaria commodities have either come down or remained stable over the past seven years, according to an analysis conducted by Frank Wafula, Ambrose Agweyu and Kate Macintyre at Aidspan. The findings of the analysis are described in a working paper published on April 29, 2013 on the Aidspan website.
There were some errors in a GFO article entitled “Significant Declines in TB Incidence, Prevalence and Mortality, but MDR-TB Remains a Threat,” first posted on 9 April and included in the GFO 214 Newsletter on 10 April.
The Grants Renewal Panel says that overall performance of a single-stream-of-funding TB grant in Nepal has been high and that there is an opportunity for scale-up in the next implementation period.
A number of strategic high-impact activities were not implemented during Phase 1 of a Round 8 TB grant in the Republic of Congo, and a significant portion of the budget was not spent, according to the Global Fund’s Grant Renewals Panel. Nevertheless, the Global Fund Board has approved new funding of $234,687 for Phase 2 of the grant. The overall Phase 2 budget recommended by the panel was approximately $2 million.
TB mortality has decreased significantly since 2000 and treatment success rates have shown steady improvement. More than half of the countries that have received Global Fund support are on track to meet the international targets for case detection, treatment success, and TB disease incidence. However, multi-drug-resistant TB (MDR-TB) remains a critical threat.
The Government of Azerbaijan has stepped up its funding for HIV, TB and malaria as a result of the departure or anticipated departure of several donors. The government has started funding opiate substitution therapy (OST) and has begun procuring antiretroviral drugs (ARVs), sufficient to meet 20% of the national need.
Global Fund Executive Director Mark Dybul says that the disease split for the funding allocated to early and interim applicants in the transition phase of the new funding model (NFM) should not be viewed in isolation, but rather in the context of all funding for 2013–2014.
Since the establishment of the Global Fund in 2002, various organisations have been formed as “Friends of the Fund.” They promote the work of the Fund and mobilise financial and political support for it.